Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Gout

Looking Forward to the Rheumatology MIPS Value Pathway

Allison Plitman  |  October 25, 2021

The field of rheumatology is leading the way in the Centers for Medicare and Medicaid Services’ new MIPS Value Pathways with rheumatology-specific quality measures and improvement activities.

Filed under:Quality Assurance/Improvement Tagged with:ACR Convergence 2021MIPSphysician quality reportingQuality MeasuresQuality Payment Program (QPP)RISE registryWilliam Harvey

New Supplement to The Rheumatologist Highlights Psoriatic Arthritis Advances

Ethan Craig, MD, MHS  |  October 15, 2021

It feels like a long decade has passed since March 2020. At The Rheumatologist, we closed out 2020 with a special supplement on gout. Physician Editor Phil Seo, MD, MHS, kicked off that supplement with, “COVID-19. Black Lives Matter. A new gout guideline. These are some of the things 2020 ushered in. And we’re unlikely…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

The Dual-Target Strategy in Rheumatoid Arthritis: Put Patients First

Ricardo J.O. Ferreira, RN, PhD; Leonard H. Calabrese, DO; & José A.P. Da Silva, MD, PhD  |  October 13, 2021

The impressive progress of medical knowledge and technology reinforces our trust in the scientific methodology that made it all possible. However, that progress also creates risks related to the primary goal of medical care: to serve our patients’ interests and enjoyment of life in the best possible way. In this article we present our views…

Filed under:ConditionsPatient PerspectiveRheumatoid ArthritisSpeak Out Rheum Tagged with:Disease Activity Score (DAS)patient centerednessshared decision makingSpeak Out RheumatologyTreat-to-Target

Practical Ways to Manage Cardiovascular Risk in Patients with Psoriatic Arthritis

Samantha C. Shapiro, MD  |  October 5, 2021

Increased cardiovascular (CV) risk in patients with rheumatic disease is old news. Over the past decade, a multitude of studies have demonstrated elevated CV risk in a variety of conditions: systemic lupus erythematosus, rheumatoid arthritis and psoriatic arthritis (PsA), to name a few. The risk in patients with rheumatic disease seems to be linked to…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

Summer 2021’s Awards, Appointments & Announcements in Rheumatology

Kelly April Tyrrell & Gretchen Henkel  |  September 14, 2021

Marian Hannan Celebrated after 10 Years as AC&R Editor-in-Chief By Kelly April Tyrrell This summer, the 10-year tenure of Marian Hannan, MPH, DSc, as editor in chief of Arthritis Care & Research (AC&R), has come to an end. Kelli Allen, PhD, assumed the post on July 1. “Marian has done a fantastic job over the…

Filed under:AwardsProfiles Tagged with:Dr. John J. O’SheaDr. Marian HannanDr. Tuhina Neogi

Using Different Fibromyalgia Criteria Affects Prevalence Estimates

Deborah Levenson  |  September 14, 2021

A recent paper illustrates how using different fibromyalgia criteria affects reports of its prevalence.1 Writing in Arthritis Care & Research, researchers found the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks–American Pain Society Pain Taxonomy (AAPT) criteria caused far more people to be categorized as having fibromyalgia than criteria put forth by…

Filed under:ConditionsPain SyndromesSoft Tissue Pain Tagged with:Classification CriteriaFibromyalgia

Minnesota Joins Dakotas to Form Growing Rheumatology Association

Linda Childers  |  September 14, 2021

A relatively new state association, the Rheumatology Association of Minnesota and the Dakotas (RA-MD), held its first meeting in 2016. Five years later, the association president, Jody Hargrove, MD, a board-certified rheumatologist with Arthritis and Rheumatology Consultants PA, Edina, Minn., says the group’s membership fluctuates between 80 and 100 rheumatology professionals. RA-MD has members from…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:State Rheumtelehealth

Case Report: A 5-Year-Old with an Ischemic Digit

Marta Michalska-Smith, MD, & Colleen K. Correll, MD, MPH  |  September 14, 2021

Janus kinase 1 and 2 inhibitors (jakinibs) have been approved for the treatment of rheumatoid arthritis, psoriatic arthritis and, most recently, juvenile idiopathic arthritis. They have also shown promise in the treatment of interferon (IFN) mediated diseases. The Janus kinase and signal transducer and activator of transcription (JAK/STAT) pathway is the principal signaling pathway for…

Filed under:Conditions Tagged with:Aicardi-Goutières SyndromeJanus Kinase Inhibitors

Vasculitis Guidelines in Focus, Part 1: The Guideline Project

Michael Putman, MD  |  August 31, 2021

Sharon A. Chung, MD, MAS, director of the vasculitis clinic at the University of California, San Francisco, served as the principal investigator of the overall vasculitis guideline effort and talks about the process here.

Filed under:Clinical Criteria/GuidelinesConditionsVasculitis Tagged with:GuidelinesVasculitisVasculitis Foundation

International Study Finds Colchicine Promising as Outpatient Treatment for COVID-19

Lara C. Pullen, PhD  |  August 17, 2021

One of the oldest treatment options in rheumatology, colchicine, may be an effective and inexpensive treatment to prevent complications in non-hospitalized patients with COVID-19, particularly in men, according to the results of large global study.

Filed under:ConditionsDrug Updates Tagged with:ColchicineCOVID-19SARS-CoV-2

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 59
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences